American Society of Hirudotherapy

Coagulation factor XI and cardiovascular disease: A complex, cardio-specific conundrum

Commentary published in Med (New York, N.Y.) (2026)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureCate et al. · Med (New York, N.Y.), 2026

Abstract

Coagulation factor XI (FXI) is an emerging target for venous and arterial thrombosis. While arterial prevention studies yield conflicting results, FXI(a) inhibition may be most effective as add-on therapy. Potential off-target cardiovascular effects, including blood pressure lowering and altered cardiac function, remain inconsistent. Ongoing trials should therefore assess both intended antithrombotic efficacy and unintended cardiovascular consequences.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansFactor XICardiovascular DiseasesThrombosis

Summary

This review discusses FXI as an emerging anticoagulation target, noting that arterial prevention studies yield conflicting results and that FXI(a) inhibition may work best as add-on therapy. Off-target cardiovascular effects such as blood pressure changes remain inconsistently reported.

Context

This perspective reviews coagulation factor XI (FXI) as an emerging target for venous and arterial thrombosis, noting that arterial prevention results are conflicting, that FXI(a) inhibition may work best as add-on therapy, and that potential off-target cardiovascular effects remain inconsistent and warrant assessment in ongoing trials. It is relevant because the contact/intrinsic coagulation pathway (FXI/FXIa) is precisely where several leech- and other hematophagous-organism-derived anticoagulant molecules act, situating leech-secretome research within a target class of active pharmaceutical interest. Caveat: this is an opinion/review summarizing and weighing others' findings rather than presenting new data, and it concerns small-molecule and biologic FXI inhibitors generally, not leech therapy specifically.

Citation

Reference (Vancouver style)

Cate VT, Sulochana HR, Cate HT, Nagy M. Coagulation factor XI and cardiovascular disease: A complex, cardio-specific conundrum. Med. 2026;7(2):100995. doi:10.1016/j.medj.2025.100995. PMID: 41690296

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.